Technical Analysis for GTBP - GT Biopharma, Inc.

Grade Last Price % Change Price Change
F 4.41 -4.75% -0.22
GTBP closed down 4.75 percent on Monday, March 18, 2024, on 36 percent of normal volume.
Earnings due: Mar 28
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
New Downtrend Bearish -4.75%
Gapped Down Weakness -4.75%
Upper Bollinger Band Walk Strength -6.37%
Inside Day Range Contraction -6.37%
Overbought Stochastic Strength -6.37%
Upper Bollinger Band Walk Strength -3.50%
Weak + Overbought Other -3.50%
Overbought Stochastic Strength -3.50%
Upper Bollinger Band Touch Strength -3.50%

   Recent Intraday Alerts

Alert Time
20 DMA Support about 17 hours ago
Down 5% about 18 hours ago
Fell Below Previous Day's Low about 18 hours ago
Fell Below 20 DMA about 18 hours ago
60 Minute Opening Range Breakdown about 20 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

GT Biopharma, Inc. Description

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based on its proprietary technology platforms. The company develops immuno-oncology product candidates, including GTB-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors, which is in Phase 2 clinical trial; GTB-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate that is in Phase 1 clinical trial; GTB-C3550, a next-generation follow-on to its lead candidates TriKE, GTB-3550, and GTB-C3550, which contains a modified CD16 moiety; and GTB-1615, a single-chain fusion protein for the treatment of solid tumors. Its central nervous system portfolio consists of GTP-004 for the treatment of myasthenia gravis, PainBrake to treat chronic neuropathic pain, and GTP-011 for the treatment of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is headquartered in Westlake Village, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Cancer Therapies Myasthenia Gravis Lectins Cd22 Coronavirus Infection Siglec Treatment Of Myasthenia Gravis

Is GTBP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.497
52 Week Low 3.52
Average Volume 11,853
200-Day Moving Average 7.33
50-Day Moving Average 5.29
20-Day Moving Average 4.38
10-Day Moving Average 4.57
Average True Range 0.37
RSI (14) 45.95
ADX 27.0
+DI 21.20
-DI 23.82
Chandelier Exit (Long, 3 ATRs) 4.02
Chandelier Exit (Short, 3 ATRs) 4.90
Upper Bollinger Bands 4.97
Lower Bollinger Band 3.79
Percent B (%b) 0.52
BandWidth 26.98
MACD Line -0.13
MACD Signal Line -0.23
MACD Histogram 0.1033
Fundamentals Value
Market Cap 6.09 Million
Num Shares 1.38 Million
EPS -9.00
Price-to-Earnings (P/E) Ratio -0.49
Price-to-Sales 0.00
Price-to-Book 0.67
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.86
Resistance 3 (R3) 4.88 4.75 4.79
Resistance 2 (R2) 4.75 4.64 4.74 4.76
Resistance 1 (R1) 4.58 4.56 4.52 4.56 4.73
Pivot Point 4.45 4.45 4.42 4.44 4.45
Support 1 (S1) 4.28 4.34 4.22 4.26 4.09
Support 2 (S2) 4.15 4.26 4.14 4.06
Support 3 (S3) 3.98 4.15 4.04
Support 4 (S4) 3.96